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Abstract 
Background: Treatment of giant cell tumour of bone (GCTB) of the distal radius/ulna poses a surgical challenge, as 
complex reconstructive surgery may be required. This study evaluates the clinical, radiological and pathological find-
ings in five cases of GCTB of the distal forearm where a 3 month course of denosumab was given prior to surgery.
Methods: Patients with biopsy proven distal forearm GCTB, treated for 3 months with denosumab, followed by 
salvage surgery (curettage and cementation) were included. Wrist pain and function were assessed using the modi-
fied Mayo Wrist Score (MMWS). Plain radiographs, MRI and PET/CT were performed pre-treatment and 2 months after 
initiation of denosumab therapy. Histological comparison was made between the original biopsy and surgical curet-
tage specimens.
Results: Five patients with an average age of 25 years were included in the study. Improvement in wrist pain and 
function was seen in all patients with the average MMWS increasing from 30 pre-treatment to 85 at 3 months. Plain 
radiographs demonstrated marginal sclerosis in all cases with reconstitution of cortical and subarticular bone by 
2 months; internal matrix sclerosis and osseous consolidation was more variable. Increased tumour heterogeneity and 
low signal were observed on T2-weighted MR images. PET/CT revealed a decrease in average SUV from 14.8 pre-treat-
ment to 4.7 at 2 months. Histology showed disappearance of osteoclasts and increased fibro-osseous tissue. Deno-
sumab treatment has the potential to facilitate salvage surgery, thus avoiding bone resection and graft reconstruc-
tion. A good outcome was achieved apart from local recurrence in one case. Follow up ranged from 17 to 54 months.
Conclusion: Distal forearm GCTB responds clinically, radiologically and histologically to a short course of pre-opera-
tive denosumab therapy, which has the potential to facilitate salvage surgery.
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Background
Giant cell tumour of bone (GCTB) is a benign but locally 
aggressive neoplasm, accounting for approximately 5% 
of primary bone tumours [1–3]; it commonly develops 
in the mature skeleton involving the epiphyseal region 
of long bones. The three most common locations where 
GCTB develops are the distal femur, proximal tibia and 
distal radius respectively.
In GCTB there is a proliferation of mononuclear stro-
mal cells which highly express receptor activator of 
nuclear factor kappa-B ligand (RANKL), and an infil-
trate of mononuclear macrophage-like cells and scattered 
multinucleated osteoclastic giant cells, both of which 
express RANK [1, 2, 4, 5]. In the presence of macrophage-
colony stimulating factor, RANK + macrophages interact 
with RANKL  +  stromal cells to induce osteoclast for-
mation. The numerous osteoclastic giant cells in GCTB 
are responsible for the extensive osteolysis that attends 
GCTB tumour growth. Denosumab is a human monoclo-
nal antibody that targets and binds with high affinity and 
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specificity to RANKL; it competitively inhibits RANK–
RANKL binding, decreasing the formation, activity and 
survival of osteoclastic giant cells in GCTB, resulting in 
reduced bone resorption [5–8].
Traditionally, GCTB has been treated surgically by 
local curettage, with or without packing of the defect 
with polymethylmethacrylate (PMMA) cement or bone 
graft, and internal fixation when needed [9–12]. The aim 
of this approach is to remove the tumour whilst preserv-
ing normal anatomy and wrist function. The reported 
recurrence rate of GCTB following this treatment is, 
however, relatively high with more frequent recurrence 
noted in the distal radius and ulna [2, 3, 12–16]. Previ-
ous studies have shown that pre-operative denosumab 
therapy makes subsequent surgery more feasible and may 
result in surgical down-staging to a less morbid surgical 
salvage procedure [17, 18] allowing for improved patient 
function. There are currently no specific guidelines on 
the optimal duration of pre-operative denosumab ther-
apy and recognising the imaging features of a positive 
tumoral response to denosumab is important for thera-
peutic decision making.
This study evaluates the clinical, radiological and 
pathological findings in five cases of GCTB of the distal 
forearm that received a planned short 3 month course of 
denosumab prior to surgery.
Methods
A retrospective review of patients presenting between 
2012 and 2015 with GCTB of the distal upper extremity 
was conducted at our institution. Patients with biopsy 
proven (Campanacci grade 2/3) GCTB of the distal ulna 
or radius treated for 3 months with denosumab followed 
by surgical curettage and cementation, and with more 
than 12  months follow up, were included in the study. 
Excluded patients were those that lacked a pre-treatment 
biopsy and/or had received prior treatment for their 
GCTB, including denosumab treatment for more than 
3 months, and/or had > 12 months follow-up.
Denosumab was administered by subcutaneous injec-
tion of 120  mg every 4  weeks with additional loading 
doses of 120 mg on days 8 and 15 of the first month. Daily 
supplements of calcium 500  mg and vitamin D 400  IU 
were taken and serum electrolytes were checked every 
4 weeks. This was performed for a total of three cycles.
Clinical data collected included age, sex, location of 
tumour, length of follow-up and complications post-sur-
gery. Patient wrist pain and function were assessed by the 
medical oncologist administering denosumab at the com-
mencement of treatment and at 4 weekly intervals for the 
3 month treatment using the modified Mayo Wrist Score 
(MMWS). Each assessment totaled 100 points divided 
among wrist pain (25 points), range of motion as a 
percentage of the opposite side (25 points), grip strength 
as a percentage of the opposite side (25 points), and the 
ability to return to regular employment or activities (25 
points).
All patients were initially assessed with plain radio-
graphs, magnetic resonance imaging, with and with-
out gadolinium contrast (MRI), and positron emission 
tomography with fluorodeoxyglucose integrated with 
computed tomography (PET/CT). These studies were 
repeated 2  months after the commencement of deno-
sumab therapy. All patients had post-operative and 
follow-up plain radiographs. All imaging studies were 
repeated if there was clinical or radiographic suspicion of 
recurrence.
Following 3  months denosumab treatment, surgical 
management consisted of careful and thorough curettage 
of all clinically visible disease, including bony septa and 
the neo-sclerotic intra-osseous margin, then painting the 
cavity with methylene blue and high speed burring of the 
sclerotic internal margins of the tumour. PMMA cement 
was used to fill the small defects created in the bone. No 
other adjuvants such as phenol or cryotherapy were used. 
The same sarcoma surgeon, with over 30  years experi-
ence, treated and followed up all cases.
In assessing the histological response to denosumab, 
comparison was made between the original biopsy speci-
men and surgical curettage specimens. The presence or 
absence of osteoclasts, the number of mononuclear stro-
mal cells and the extent of fibrous matrix/bone formation 
was noted.
Results
Between May 2012 and July 2015, five patients fulfill-
ing the inclusion criteria  were referred to our unit with 
GCTB of the distal forearm. There were four females and 
one male with an average age of 25 years.
Pre‑denosumab treatment findings
Clinical
The patients presented with increasing wrist pain 
(n = 5), wrist swelling (n = 4), reduced wrist grip (n = 3), 
reduced wrist movement and function (n = 5). The aver-
age MMWS score prior to treatment was 30. Table 1 pre-
sents demographic, clinical and radiological data on the 
cases in this study.
Radiological
Initial plain radiographs demonstrated in all cases a 
solitary, expansile, lytic lesion involving the epiphy-
sis and extending up to the articular surface of the dis-
tal radius (n = 4) or ulna (n = 1). The physis was fused 
in all patients. Four lesions were graded as Campanacci 
grade 2 (active). These showed eccentric expansion of 
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bone with associated cortical thinning but no cortical de-
struction or pathologic fracture (Figs. 1a, 2a, 3a, 4a). One 
lesion was graded as Campanacci grade 3 (aggressive) 
with cortical breach of the radial styloid articular sur-
face (Fig. 5a). MRI showed expansile subarticular lesions 
returning low to isointense signal relative to surrounding 
muscle on T1-weighted imaging (Fig.  3c) and heteroge-
neous predominantly high STIR and T2-weighted signal 
intensity (Figs. 3b, 4b). Gadolinium was administered in 
three cases and demonstrated diffuse enhancement in all 
cases. There were fluid–fluid levels in one patient indica-
tive of secondary aneurysmal bone cyst change (Fig. 2b). 
There was a focal breach of the radial styloid articular 
surface with a small amount of soft-tissue extending into 
the radial aspect of the carpal joint in the Campanacci 
grade 3 lesion. In the remaining cases, the articular sur-
face appeared intact. PET/CT revealed lytic, expansile 
lesions without a sclerotic rim and marked cortical thin-
ning with an increased standardized uptake value (SUV) 
in all cases (Figs. 4c, 5b). The average pre-treatment SUV 
was 14.8 (Table 1). There were no distant lesions and the 
lungs were clear in all patients.
Histological
The diagnosis of GCTB was histologically confirmed pre-
treatment in all cases. Histology showed a proliferation 
of mononuclear stromal cells, numerous macrophages 
and frequent scattered osteoclast-like giant cells, some of 
which were very large and contained a large number of 
nuclei (Fig. 6a).
Post‑denosumab treatment findings
Clinical
Denosumab treatment was administrated for 3  months 
pre-surgery; it was generally well tolerated and the 
patients had no serious treatment-related adverse events. 
In all patients a decrease in wrist pain and improved wrist 
function was noted within 2 months of commencing den-
osumab therapy, with the average MMWS increasing to 
75. The MMWS increased further to 85 at 3 months.
Radiological
Two months following the commencement of deno-
sumab treatment, plain radiographs showed well-defined 
marginal sclerosis with reconstitution and mineralization 
of cortical bone in all cases. Varying degrees of inter-
nal matrix sclerosis and osseous consolidation resulted 
in increased radiopacity of the lesions (Figs.  1b, 2c, 3d, 
5c). Cortical sclerosis resulted in mild cortical irregular-
ity and modeling deformity involving the articular sur-
face in two cases (Figs.  1b, 3d). The Campanacci grade 
2 lesions showed no significant change in tumour size. 
The Campanacci grade 3 lesion showed a 15% increase in 
tumour volume in addition to considerable marginal and 
Fig. 1 Patient 1: pre denosumab, a frontal plain radiograph shows a lytic Campanacci grade 2 distal radial GCTB with mild expansion and cortical 
thinning (arrow). Post denosumab at 2 months, b frontal plain radiograph demonstrates sclerosis of the tumour margin (arrows) and radial articular 
surface. There is mild modeling deformity of the radial articular surface and moderate internal matrix osteosclerosis. Post surgical, c frontal plain 
radiograph 1 week post surgical curettage, cementoplasty and internal fixation shows lucency of the peripheral tumour cavity (arrows) and d 
2 years post surgery with progressive infilling of the lesion with osteosclerosis around the cement despite no post operative denosumab therapy 
(arrows)
Page 5 of 11McCarthy et al. Clin Sarcoma Res  (2017) 7:19 
matrix sclerosis after 2 months of denosumab treatment 
(Fig. 5c). MRI showed increased low signal marginal scle-
rosis with clearer definition of cortical margins (Fig. 3e, 
f ). The articular surface appeared intact in all cases with 
no soft tissue mass. There was no significant change in 
T1 weighted signal (Fig. 3f ). T2 weighted signal appeared 
more heterogeneous post-treatment with new areas of 
internal low T2 signal along with multiple central non-
enhancing areas post-gadolinium (Figs. 3e, 4d). PET/CT 
confirmed radiologic evidence of bone repair with mar-
ginal and intralesional osteosclerosis in all patients. The 
average SUV at 2 months after commencing denosumab 
decreased to 4.7 (Figs. 4e, 5d; Table 1).
Histological
Histopathological examination of the treated GCTBs 
showed an absence of osteoclasts and an increase in 
well-vascularized cellular fibrous and fibrosseous tissue 
with focal areas of osteoid and woven bone formation 
(Fig. 6b); these were of variable thickness and shape and 
covered partly by bone lining cells. There were scattered 
macrophage-like cells but no giant cells were observed. 
There was no mitotic activity or nuclear pleomorphism of 
stromal cells, which appeared reduced in number within 
cellular fibrous tissue. The lesions were surrounded by 
organised reactive bone.
Outcome following denosumab treatment and salvage 
surgery
Curettage of the GCTB with insertion of PMMA cement 
was performed an average of 28  days after cessation of 
denosumab treatment. Internal fixation was used in one 
case due to bone destruction that necessitated support 
of the distal radial joint surface (Fig. 1c). There were no 
intraoperative complications.
Average follow-up was 37  months (Table  1). Four 
patients had a good clinical and functional outcome with 
no post-surgery complications or evidence of recurrence. 
One of these patients demonstrated progressive infilling 
of the tumour with osteosclerosis around the cement on 
plain radiographs over 2  years (Fig.  1d) despite no fur-
ther denosumab therapy; this did not result in increased 
symptoms. One patient with the Campanacci grade 3 
lesion had local tumor recurrence 2  months post-sur-
gery; this was evident from radiographic imaging which 
showed progressive bone destruction with involvement 
of the radio-carpal joint (Fig. 5e). Resection of the distal 
radius with a vascularized free fibular graft (VFFG) and 
joint reconstruction was performed 7  months after ini-
tial surgery in this case. Twenty-three months after this 
intervention there has been no evidence of recurrence.
None of the patients has shown evidence of distal 
disease.
Fig. 2 Patient 2: pre denosumab, a frontal plain radiograph shows a lytic Campanacci grade 2 distal radial GCTB with medial expansion and cortical 
thinning (arrow). b Sagittal T2-weighted MR image demonstrates volar expansion and fluid fluid levels (arrows) indicating secondary aneurysmal 
bone cyst. Post denosumab at 2 months, c frontal plain radiograph demonstrates more clearly defined sclerotic tumour margins particularly along 
the expansile medial aspect of the lesion (arrows) and mild matrix osteosclerosis
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Discussion
GCTB is a benign but locally aggressive tumour that 
occurs most commonly in a relatively young patient 
population. The distal radius is the third most com-
mon location where GCTB develops and, as in other 
sites, curettage of the tumour and cementation is often 
employed as first-line treatment [12, 16, 19–21]. How-
ever, distal radius/ulna GCTBs frequently recur follow-
ing this treatment, usually within the first 2  years [22] 
and complex reconstructive surgery is often required, not 
only to limit local recurrence but also to preserve func-
tional anatomy [12, 23].
There are a few previous case reports describing the 
effect of denosumab treatment on GCTB of the distal 
radius. A beneficial effect of denosumab was noted on a 
GCTB of the distal radius [24] and a locally aggressive 
giant cell-containing lesion of the radius diagnosed as 
aneurysmal bone cyst, a lesion which is also known 
to contain stromal cells that express RANKL [25, 26]. 
Matcuk et  al. [27] noted rapid recurrence and aggres-
sive growth of a GCTB after the cessation of long-term 
denosumab therapy, indicating that surgery is important 
in managing these tumours. This is the first case series 
examining the effect of a pre-operative short course 
of denosumab treatment on GCTB in bones of the dis-
tal forearm. As such, there are no guidelines on patient 
selection or optimal treatment in terms of dose and 
duration of denosumab administration; our denosumab 
schedule was based on previous phase 2 studies [6, 18, 
28]. Denosumab was well tolerated in our cases, none of 
whom reported any of the known side effects of this drug 
[7, 8, 18].
Fig. 3 Patient 3: pre denosumab, a frontal plain radiograph demonstrates a Campanacci grade 2 distal ulnar GCTB with mild expansion and cortical 
thinning. b Axial T2-weighted fat saturated and c axial T1-weighted MR images confirm an expansile heterogeneous predominantly high T2- and 
low to isointense T1-weighted distal ulnar lesion (U ulnar, R radius). Post denosumab at 2 months, d frontal plain radiograph shows marginal scle-
rosis and internal matrix sclerosis, with mild modeling deformity of the ulnar articular surface (black arrow). e Axial T2-weighted fat saturated and f 
axial T1-weighted MR images show definition of cortical margins with the formation of marginal sclerosis seen as peripheral low T1 and T2-W signal 
(white arrows). The tumour matrix is more heterogeneous with areas of low T2-W signal reflecting internal matrix consolidation (R radius)
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The origin of pain in GCTB is multifactorial including 
mechanical stress from tumour related pressure, tumour 
growth with expansion of the periosteum, the loss of 
structurally significant bone and mechanical failure. The 
production of prostaglandins, endothelins and other nox-
ious factors by the tumour cells are also known to result 
in pain [28]. Clinically, all five patients showed a signifi-
cant decrease in wrist pain within 8 weeks of commenc-
ing denosumab therapy. This is in keeping with previous 
studies, which reported a clinically relevant decrease in 
pain with low or no analgesic use in most patients within 
2 months of commencing denosumab therapy [6, 18, 28]. 
Fig. 4 Patient 4: pre denosumab, a frontal plain radiograph demonstrates a lytic expansile Campanacci grade 2 distal radial GCTB with cortical 
thinning. b Coronal STIR MR image shows the lesion returns heterogeneous predominantly high STIR MR signal. c Fused PET/CT image illustrates 
marked FDG uptake with a standardized uptake value (SUV) of 17 (arrow). Post denosumab at 2 months, d coronal STIR MR image shows increased 
heterogeneity of MR signal with areas of low STIR signal reflecting matrix osteosclerosis (white arrows). e Fused PET/CT image confirms a significant 
decrease in FDG uptake with an SUV of 4.8 and the formation of marginal sclerosis (red arrows)
Page 8 of 11McCarthy et al. Clin Sarcoma Res  (2017) 7:19 
Improved wrist mobility and function was also noted in 
all patients within 8 weeks of denosumab therapy as seen 
in prior studies [6, 28].
Radiological features indicative of a positive response to 
denosumab are marginal sclerosis of the tumour and cor-
tical thickening which was clearly seen all patients after 
2  months of denosumab treatment. Similar radiologi-
cal findings have been described in other studies where 
denosumab treatment ranged from 2  months to 2  years 
[27, 29–33]. One of our cases demonstrated reconstitu-
tion of cortical bone with repair of a focal defect in the 
articular surface. Intralesional consolidation was more 
variable with mild to more marked matrix osteosclerosis. 
In our cases, marginal and intralesional osteosclerosis was 
best appreciated on plain radiographs and the CT compo-
nent of the PET/CT. PET/CT also revealed a decrease in 
Fig. 5 Patient 5: pre denosumab, a frontal plain radiograph illustrates a distal radial GCTB with moderate expansion and cortical thinning. A breach 
of the radial styloid articular surface (arrow) with soft tissue extending into the carpal joint was confirmed on MR imaging and this lesion was 
graded as Campanacci grade 3. b Fused PET/CT image confirms marked metabolic activity with an increased SUV of 19.5 (arrow). Post denosumab 
at 2 months, c frontal plain radiograph demonstrates an increase in size of the lesion despite marginal sclerosis with reconstitution of the radial 
articular surface (arrow) and quite marked intralesional matrix consolidation. d Fused PET/CT image confirms reduced activity of the lesion with a 
significant decrease in the SUV to 4.5 (arrow). Post surgical, e frontal plain radiograph 2 months post surgery shows tumour recurrence with rapid 
growth, progressive bone destruction and extrusion of cement (arrow)
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average SUV from 14.8 pre-treatment to 4.7 at 2 months, 
indicating that PET/CT may be a sensitive monitor for 
the response to denosumab. MRI did not aid in evaluat-
ing the efficacy of denosumab therapy, although increased 
tumour heterogeneity on T2-weighted images with areas 
of decreased gadolinium uptake were observed. MRI 
findings of increased intralesional heterogeneity, cortical 
thickening and irregularity and linear perilesional fluid 
like signal following short term denosumab therapy have 
previously been described and misinterpreted as disease 
progression [33]. These MR features were present in our 
cases and represent an appropriate response to deno-
sumab treatment. It has been suggested that increased 
MRI tumour heterogeneity and T2 low signal may reflect 
central necrosis and osteosclerosis in the tumour [29, 
30]. Histopathological findings in our denosumab treated 
cases did not show evidence of necrosis but did show 
prominent intralesional ossification and fibrosis, disap-
pearance of osteoclastic giant cells and a reduction in 
the number of mononuclear stromal cells, as previously 
described [6, 29, 30, 34, 35].
In one of our cases, ongoing post operative infilling and 
sclerosis was noted around the cement on plain radio-
graphs despite no post-operative denosumab treatment. 
This case continues to have an excellent clinical and radi-
ological response with no evidence of recurrent symp-
toms or tumour 3 years and 9 months post surgery. The 
findings in this case suggest that there may be some con-
tinued response to short term denosumab therapy.
An overall reduction in GCTB size has been noted fol-
lowing denosumab treatment for an average duration of 
15.3 (12.1–23.6) months [17]. In our series none of the 
lesions decreased in size when imaged after 2 months of 
denosumab treatment and the Campanacci grade 3 lesion 
was larger than on presentation radiographs.
Local recurrence occurred in one case, the Campanacci 
grade 3 lesion that had aggressive radiological features 
pre-denosumab with involvement of the cortex, breach of 
the radial styloid articular surface and a small soft tissue 
mass evident on MRI. In this case, after 2 months of den-
osumab treatment, despite an overall increase in tumour 
size, disappearance of the soft tissue component and 
reconstitution of the articular cortex, was noted, as well 
as matrix osteosclerosis and reduced metabolic activ-
ity on PET (SUV 19.5–4.5). This allowed the patient the 
opportunity of initial surgical curettage with the chance 
for an improved functional outcome.
Previous studies have shown that denosumab results 
in a decrease in tumour progression, with surgical 
down-staging to a less morbid surgical salvage proce-
dure than originally planned in 38% (n =  84/222; aver-
age duration of denosumab treatment 15.3 months) and 
61% (n =  16/26; average duration of denosumab treat-
ment 6 months) of patients [17, 18]. In our experience of 
treating GCTBs with neoadjuvant denosumab, we found 
that treatment for more than 3  months often resulted 
in marked intralesional sclerosis and extensive perile-
sional new bone formation. This makes curettage of some 
GCTBs more difficult, and, as noted by some observers 
[36], can create uncertainty with regard to the adequacy 
of tumour excision. In this study we show that a short 
course of denosumab results in reconstitution of cortical 
and subarticular bone and sufficient marginal sclerosis 
to define the tumour margin whilst not causing marked 
intralesional sclerosis. The sarcoma surgeon who treated 
all cases, was of the opinion that this treatment regime 
facilitated curettage of the lesion with preservation of the 
native joint, local functional anatomy and wrist function.
It has been suggested that, although the newly 
formed bone at the tumour periphery allows for a 
Fig. 6 Histology: pre denosumab, a numerous osteoclast-like giant cells, some of which have a very large number of nuclei, and surrounding mon-
onuclear cells. Post denosumab, b well-vascularised fibrous tissue in which there is focal osteoid/woven bone formation and absence of osteoclasts
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sufficient mechanical scaffold for curettage to be done 
without fear of the bone collapsing, this rim of scle-
rotic bone may contain neoplastic stromal cells that 
may become active and express RANKL after deno-
sumab treatment is stopped [36]. Another advan-
tage of performing curettage earlier following a short 
course of denosumab is prevention of too thick a rim 
of peripheral bone from being formed; this decreases 
the chances of neoplastic tissue being left behind 
post-curettage in the thickened rim of perilesional 
new bone thus facilitating complete tumour removal. 
A recent study of 35 patients with locally advanced 
Campanacci grade 3 GCTB supports a short course 
(3  months) of denosumab treatment prior to surgi-
cal curettage; however, postulates that a longer dura-
tion of denosumab therapy should be administered 
for en bloc tumour resection, which may be facilitated 
by more marked tumour sclerosis with a lower risk of 
recurrence [35].
Conclusion
Our results indicate that GCTB of the distal forearm 
responds clinically, radiologically and histologically within 
3  months of denosumab treatment. Short term deno-
sumab was well tolerated and thought to facilitate surgi-
cal curettage in all cases, with preservation of the native 
joint and a good surgical outcome apart from one case of 
recurrence in a Campanacci grade 3 lesion. Limitations 
of this study include its retrospective nature, and clearly 
small sample size. However, the rarity of GCTB, espe-
cially with regard to a particular anatomic site makes the 
reporting of larger numbers challenging in a single insti-
tution. Co-ordinated, multi-institutional studies are likely 
to be needed in order to fully assess this treatment regime 
and whether a short course of neoadjuvant denosumab 
would be similarly effective for GCTBs in other bones.
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